Your browser doesn't support javascript.
loading
Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.
Wang, Xiaoli; Qiao, Guoliang; Jiang, Ni; Morse, Michael A; Zhou, Xinna; Wang, Shuo; Wu, Jiangping; Song, Yuguang; Zhao, Yanjie; Zhou, Lei; Yuan, Yanhua; Hobeika, Amy; Ren, Jun; Lyerly, Herbert Kim.
Afiliación
  • Wang X; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Qiao G; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Jiang N; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Morse MA; Department of Surgery, Duke University Medical Center Durham, NC 27710, USA.
  • Zhou X; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Wang S; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Wu J; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Song Y; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Zhao Y; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Zhou L; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Yuan Y; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Hobeika A; Department of Surgery, Duke University Medical Center Durham, NC 27710, USA.
  • Ren J; Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital Beijing 100038, China.
  • Lyerly HK; Department of Surgery, Duke University Medical Center Durham, NC 27710, USA.
Am J Cancer Res ; 11(4): 1709-1718, 2021.
Article en En | MEDLINE | ID: mdl-33948384
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Cancer Res Año: 2021 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Cancer Res Año: 2021 Tipo del documento: Article País de afiliación: China